MDS Pharma Services, the CRO headquartered in Canada, moved its Beijing lab to a much larger facility. The new 25,000 square foot space affords five times the space for testing, four times the space for producing clinical trial kits, and a greater number of clinical trial testing services. In announcing the move, MDS noted that it was the first western CRO to own its testing facility in China. During the 10 years MDS has been operating in China, it has managed more than 30,000 patients in clinical trials. More details...

Stock Symbol: (NYSE: MDZ)